Sec Form 3 Filing - JOHNSON & JOHNSON @ CVRx, Inc. - 2021-06-29

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person JOHNSON & JOHNSON 2. Issuer Name and Ticker or Trading Symbol CVRx, Inc. [ CVRX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) ONE JOHNSON & JOHNSON PLAZA 3. Date of Earliest Transaction (MM/DD/YY) 06/29/2021 (Street) NEW BRUNSWICK, NJ08933 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series D-2 Preferred Stock ( 2 ) ( 1 ) ( 1 ) Common Stock 101,958 I See footnote ( 3 ) Series E-2 Preferred Stock ( 2 ) ( 1 ) ( 1 ) Common Stock 163,123 I See footnote ( 3 ) Series F-2 Preferred Stock ( 2 ) ( 1 ) ( 1 ) Common Stock 191,864 I See footnote ( 3 ) Series G Preferred Stock ( 4 ) ( 1 ) ( 1 ) Common Stock 3,038,630 I See footnote ( 3 ) Warrant to Purchase Series G Preferred Stock $ 0.4 ( 5 ) ( 5 ) Common Stock 607,725 I See footnote ( 6 ) Stock Option (Right to Buy) $ 0.237 ( 7 ) 12/14/2023 Common Stock 237 I See footnote ( 3 ) Stock Option (Right to Buy) $ 0.237 ( 7 ) 11/18/2024 Common Stock 158 I See footnote ( 3 ) Stock Option (Right to Buy) $ 0.237 ( 7 ) 08/06/2025 Common Stock 189 I See footnote ( 3 ) Stock Option (Right to Buy) $ 0.237 ( 7 ) 08/06/2025 Common Stock 165 I See footnote ( 3 ) Stock Option (Right to Buy) $ 0.237 ( 7 ) 08/06/2025 Common Stock 118 I See footnote ( 3 ) Stock Option (Right to Buy) $ 0.237 ( 7 ) 08/06/2025 Common Stock 71 I See footnote ( 3 ) Stock Option (Right to Buy) $ 0.237 ( 7 ) 08/06/2025 Common Stock 23 I See footnote ( 3 ) Stock Option (Right to Buy) $ 0.237 ( 7 ) 11/09/2025 Common Stock 85 I See footnote ( 3 ) Stock Option (Right to Buy) $ 0.237 ( 7 ) 02/01/2027 Common Stock 758 I See footnote ( 3 ) Stock Option (Right to Buy) $ 0.237 ( 7 ) 02/01/2027 Common Stock 489 I See footnote ( 3 ) Stock Option (Right to Buy) $ 0.237 ( 8 ) 02/15/2028 Common Stock 758 I See footnote ( 3 ) Stock Option (Right to Buy) $ 0.237 ( 8 ) 02/15/2028 Common Stock 300 I See footnote ( 3 ) Stock Option (Right to Buy) $ 1.186 ( 9 ) 11/28/2028 Common Stock 758 I See footnote ( 3 ) Stock Option (Right to Buy) $ 1.186 ( 9 ) 11/28/2028 Common Stock 142 I See footnote ( 3 ) Stock Option (Right to Buy) $ 3.955 ( 10 ) 12/05/2029 Common Stock 758 I See footnote ( 3 ) Stock Option (Right to Buy) $ 5.141 ( 11 ) 01/04/2031 Common Stock 1,264 I See footnote ( 3 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ08933 X Johnson & Johnson Innovation - JJDC, Inc. 410 GEORGE STREET NEW BRUNSWICK, NJ08901 X Signatures Johnson & Johnson By: /s/ Matthew Orlando, Secretary 06/29/2021 Signature of Reporting Person Date Johnson & Johnson Innovation - JJDC, Inc. By: /s/ Sergio Calvo-Regueros, Assistant Treasurer 06/29/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Each share of preferred stock is convertible, at the option of the holder, into shares of Common Stock at the then-effective conversion ratio for no additional consideration and has no expiration date. The shares of preferred stock will automatically convert into shares of Common Stock at the then-applicable conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares) upon the closing of the Issuer's initial public offering. The conversion rates reported reflect the conversion ratios under the Issuer's certificate of incorporation, adjusted to give effect to the previously effected 1-for-39.548 reverse stock split of the Common Stock. ( 2 )Shares of Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock are convertible into shares of Common Stock at a rate of 1-for-0.025857287. ( 3 )These securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. ( 4 )Shares of Series G Preferred Stock are convertible into shares of Common Stock at a rate of 1-for-0.0632143218. ( 5 )The Warrant to Purchase Series G Preferred Shares shall become exercisable for Common Stock upon the closing of the Issuer's initial public offering and expires on the earlier of (i) an acquisition or asset transfer involving the Issuer or (ii) 180 days after receipt of the data from a certain clinical trial. ( 6 )These securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Biosense Webster, Inc., an affiliate of Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. ( 7 )Fully vested. ( 8 )Vests as to 1/48th of the shares each month commencing March 16, 2018. ( 9 )Vests as to 1/48th of the shares each month commencing December 29, 2018. ( 10 )Vests as to 1/48th of the shares each month commencing January 6, 2020. ( 11 )Vests as to 1/48th of the shares each month commencing January 11, 2021.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.